The aging patient with hemophilia


  • Barbara A. Konkle

    Corresponding author
    1. Hematologist, Hemophilia Care Program, Director, Translational Research, Puget Sound Blood Center, Professor of Medicine/Hematology, University of Washington School of Medicine, Seattle, Washington
    • Puget Sound Blood Center, 921 Terry Avenue, Seattle, WA 98104
    Search for more papers by this author

  • Conflict of Interest: The author has received funding for research (Baxter Bioscience, Biogen-Idec Hemophilia, Inspiration, and consultancy (Baxter Bioscience, CSL Behring).


The prospects for many boys born with hemophilia today include a normal life expectancy and minimal to no joint disease. However, despite the availability of safe replacement clotting factor concentrates and effective antiviral treatment, the aging patient with hemophilia today faces many challenges. These include management of their hemophilia as well as the same age-related health issues as experienced in the general population. While increasing, data on the prevalence of comorbidities and their management in the hemophilia population remain limited. This review will focus on issues related to management of hemophilia and complications of cardiovascular, musculoskeletal, hepatic, and renal disease. Available research is summarized and potential approaches to management are discussed. Am. J. Hematol. 2012. © 2012 Wiley Periodicals, Inc.